Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rongqingbaohuashuan powder plus metformin and atorvastatin in type 2 diabetes mellitus
ChiCTR2200065431Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Rongqingbaohuashuan in type 2 diabetes mellitus (T2DM) and carotid atheroma (CAS) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Blood glucose and Carotid atherosclerotic plaque. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Rongqingbaohuashuan
03
Conditions
type 2 diabetes mellitus (T2DM)carotid atheroma (CAS)
Beyond the preview
Go deeper on ChiCTR2200065431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065431.